Overview

Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study

Status:
Recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to explore a prognostic clinical and molecular biomarker profile in a population of BRCA wild-type recurrent high-grade ovarian cancer patients treated with olaparib as maintenance after response to a platinum based therapy as platinum sensitive recurrence treatment.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute, Naples

Treatments:

Olaparib